Home › Companies › ONCY

Oncolytics Biotech

Market cap $51.7M 136.1M shares (10-Q, Nov 13, 2026) × $0.380 close Nov 17, 2026

Most recent annual filing: 2026-03-30

Catalyst timeline

11 trackedQuarter catalyst calendar →
  1. REO 033 Part A interim2026REO 033 Part A interim, 2026, major
  2. Anal cancer pivotal start2H 2026Anal cancer pivotal start, 2H 2026, routine
  3. Pelareorep partnership2H 2026Pelareorep partnership, 2H 2026, routine
  4. Revolution Medicines RAS(ON) colorectal strategy4Q 2026Revolution Medicines RAS(ON) colorectal strategy, 4Q 2026, routine
  5. RAS-inhibitor combination preclinical readoutfall or winter of 2026RAS-inhibitor combination preclinical readout, fall or winter of 2026, notable
  6. REO 033 Part B trial1Q 2027REO 033 Part B trial, 1Q 2027, notable
  7. GOBLET Cohort 5 pancreatic interim1H 2027GOBLET Cohort 5 pancreatic interim, 1H 2027, notable
  8. SCAC/anal cancer study with Coherus1Q 2027SCAC/anal cancer study with Coherus, 1Q 2027, routine
  9. Common shares listing updateJan 19, 2027Common shares listing update, Jan 19, 2027, notable
  10. Zanzalintinib plus atezolizumab Exelixis PDUFAMar 3, 2027Zanzalintinib plus atezolizumab Exelixis PDUFA, Mar 3, 2027, material
  11. REO 033 toplineAug 30, 2027REO 033 topline, Aug 30, 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Discontinued (1)

Capital (as filed)

Cash
$2.4M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$6.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$2.4M cash, runway about one month from September 30 per the update of Nov 13, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Oncolytics Biotech, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Avoid Oncolytics Biotech (ONCY) - Scientific Deep Dive for Pelareorep and Pipeline Products Twenty-eight years of pharmacodynamic receipts have not produced a randomized benefit, the one randomized colorectal precedent was negative on PFS, and the trial is funded by an ATM drip at 77 cents with a reverse split and Nasdaq deadline looming — revisit only when REO 033 reports randomized Part A data with both arms' denominators and a partner funds Part B.
  2. Avoid UPDATE: Oncolytics Biotech (ONCY) - The Draft Footnote GOBLET final data restated DOR without a response rate or denominator, the anal cancer program remains unfunded with no partner, dilution per dollar raised has roughly doubled, and only randomized REO 033 Part A data with full denominators and outside funding for Part B would change the thesis.
  3. Avoid UPDATE: Oncolytics Biotech (ONCY) - A Month of Cash and a Borrowed PD-1 Q3 shows only $2.4M cash, ATM sales below 50 cents, a widening stockholders' deficit, a Nasdaq deadline of January 15, and REO 033 enrollment described in words suggesting a thin year-end dataset — the Coherus toripalimab supply deal addresses the right population but is not a partnership or registration-grade study.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (45)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 28, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

48 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)